Anders Research

Anders Research

Home
Archive
About

Sitemap - 2023 - Anders Research

BioVie: Cautiously Optimistic Ahead of Phase 3 Alzheimer’s Data Unblinding

Relmada And REL-1017: Intriguing Underlying Efficacy In MDD Ahead Of Eventful 2024

Immix Biopharma: A Mid-To-Late Stage CAR-T Biotech Quietly Gaining Momentum

Annovis: Making Sense of the Interim Analysis

Annovis and Buntanetap: Asymmetric Risk/Reward Ahead of Interim Phase 3 Parkinson’s Data Readout

© 2025 Riley Mullin
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share